Table 1.
Demonstrates the baseline characteristics and the morphologic endoscopic findings
| IPMN patients | Other pancreatic cysts | P value | |
|---|---|---|---|
| Number of patients | 117 | 41 | - |
| Age (years), mean ± SD | 74.6 ± 10.4 | 61.1 ± 14 | < 0.001 |
| Gender, N (%) | 0.8 | ||
|
• Male • Female |
49 (41.9) 68 (58.1) |
18 (43.9) 23 (56.1) |
|
| Family history of pancreatic cancer, N (%) | 3 (2.6) | 1 (2.4) | 0.1 |
| Smoking, N (%) | 6 (5.1) | 2 (4.9) | 0.1 |
| Background liver diseases, N (%) | |||
|
Cholestatic liver disease Other liver disease (HCV) |
0 6 (5.1) |
0 0 |
0.3 |
| Personal history of cancer, N (%) | 22 (18.8) | 5 (12.2) | 0.4 |
| Alcohol consumption, N (%) | 1 (0.9) | 2 (4.9) | 0.1 |
| Gallbladder stone by EUS, N (%) | 23 (19.7) | 3 (7.3) | 0.08 |
| Signs of chronic pancreatitis, N (%) | 2 (1.7) | 2 (4.9) | 0.2 |
| Gallbladder in situ, N (%) | 93 (80) | 37 (90.2) | 0.1 |
| Cyst size by EUS (mm), mean ± SD | 15.7 ± 10.4 | 26.6 ± 20.7 | < 0.001 |
| CBD dilation by EUS, N (%) | 34 (29.1) | 4 (9.7) | 0.01 |
| CBD diameter by EUS (mm), mean ± SD | 7 ± 2.3 (3–17) | 6.3 ± 1.1 (6-10.7) | 0.06 |
| Amylase level (U/L), mean | 72,204 | 23,584 | 0.03 |
| CEA level (ng/mL), mean | 1325 | 441 | 0.05 |